LGND
Ligand Pharmaceuticals Incorporated
Price Chart
Latest Quote
$293.88
+8.97 (+3.15%)
Current Price
| Previous Close | $284.91 |
| Open | $288.34 |
| Day High | $298.54 |
| Day Low | $288.34 |
| Volume | 353,426 |
Stock Information
| Shares Outstanding | 20.04M |
| Total Debt | $451.98M |
| Cash Equivalents | $779.40M |
| Revenue | $274.48M |
| Net Income | $153.56M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.89B |
| P/E Ratio | 38.37 |
| EPS (TTM) | $7.66 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.38B |
| Sales | $274.48M |
| Income | $153.56M |
| Book/sh | $49.79 |
| Cash/sh | $38.89 |
| Employees | 47 |
Financial Ratios
| Quick Ratio | 20.81 |
| Current Ratio | 21.28 |
| Debt/Eq | 45.32 |
Returns & Margins
| ROA | 5.19% |
| ROE | 17.13% |
| Gross Margin | 83.16% |
| Operating Margin | 33.58% |
| Profit Margin | 55.95% |
Ownership
| Insider Ownership | 2.38% |
| Institutional Ownership | 106.36% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 25.97 |
| PEG | 1.53 |
| P/S | 21.46 |
| P/B | 5.90 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $277.60 |
Technical Indicators
| SMA20 | $252.14 |
| SMA50 | $236.02 |
| SMA200 | $203.67 |
| RSI | 82.95 |
| ATR | 11.9432 |
| Shares Float | 19.53M |
| Short Float | 9.79% |
| Short Ratio | 7.45 |
| Volatility | 1.04 |
| Rel Volume | 0.91 |
Performance History
| Week | +11.68% |
| Month | +24.88% |
| Quarter | +43.66% |
| 6 Months | +48.45% |
| YTD | +54.58% |
| Year | +148.59% |
| 3 Years | +280.23% |
| 5 Years | +268.61% |
| 10 Years | +316.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $293.88 | 353,426 |
| 2026-06-24 | $284.91 | 548,900 |
| 2026-06-23 | $279.44 | 2,298,200 |
| 2026-06-22 | $262.17 | 819,500 |
| 2026-06-18 | $274.88 | 609,600 |
| 2026-06-17 | $263.14 | 355,000 |
| 2026-06-16 | $255.25 | 220,600 |
| 2026-06-15 | $253.25 | 159,000 |
| 2026-06-12 | $255.54 | 247,100 |
| 2026-06-11 | $254.57 | 274,600 |
| 2026-06-10 | $248.24 | 240,000 |
| 2026-06-09 | $243.28 | 173,500 |
| 2026-06-08 | $237.75 | 219,200 |
| 2026-06-05 | $237.00 | 174,900 |
| 2026-06-04 | $235.91 | 210,400 |
| 2026-06-03 | $234.40 | 157,000 |
| 2026-06-02 | $232.76 | 185,100 |
| 2026-06-01 | $229.78 | 203,700 |
| 2026-05-29 | $231.96 | 153,600 |
| 2026-05-28 | $234.66 | 126,400 |
| 2026-05-27 | $235.89 | 189,800 |
| 2026-05-26 | $235.33 | 222,300 |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
đ° Latest News
Ligand Pharmaceuticals Director Unloads 2,501 Shares â Should You Be Concerned?
Motley Fool âĸ 2026-06-14T11:20:01Z
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Motley Fool âĸ 2026-06-07T12:48:38Z
How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets
Simply Wall St. âĸ 2026-06-01T13:17:14Z
Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy?
Motley Fool âĸ 2026-05-30T20:19:19Z
OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake?
Motley Fool âĸ 2026-05-29T22:47:31Z
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million?
Motley Fool âĸ 2026-05-19T14:18:01Z
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares?
Motley Fool âĸ 2026-05-16T14:10:01Z
Ligand Pharmaceuticals' (NASDAQ:LGND) Strong Earnings Are Of Good Quality
Simply Wall St. âĸ 2026-05-15T12:25:26Z
Ligand (LGND) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-12T16:16:04Z
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination
Simply Wall St. âĸ 2026-05-12T11:15:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $13,482,000 | $8,794,000 | $7,645,000 | $35,530,000 |
| Cost Of Revenue | $14,549,000 | $11,074,000 | $10,512,000 | $52,827,000 |
| Total Revenue | $268,087,000 | $167,133,000 | $131,314,000 | $196,245,000 |
| Operating Revenue | $268,087,000 | $167,133,000 | $131,314,000 | $196,245,000 |
| Expenses | ||||
| Interest Expense | $4,715,000 | $3,037,000 | $656,000 | $1,799,000 |
| Total Expenses | $220,888,000 | $144,112,000 | $121,493,000 | $193,208,000 |
| Other Income Expense | $102,817,000 | $-25,521,000 | $46,784,000 | $32,727,000 |
| Other Non Operating Income Expenses | $-89,000 | $-20,317,000 | $-1,702,000 | $4,187,000 |
| Net Non Operating Interest Income Expense | $8,944,000 | $5,018,000 | $7,055,000 | $247,000 |
| Interest Expense Non Operating | $4,715,000 | $3,037,000 | $656,000 | $1,799,000 |
| Operating Expense | $206,339,000 | $133,038,000 | $110,981,000 | $140,381,000 |
| General And Administrative Expense | $92,449,000 | $78,654,000 | $52,790,000 | $70,062,000 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $124,453,000 | $-4,032,000 | $53,819,000 | $-5,219,000 |
| Net Interest Income | $8,944,000 | $5,018,000 | $7,055,000 | $247,000 |
| Interest Income | $13,659,000 | $8,055,000 | $7,711,000 | $2,046,000 |
| Normalized Income | $43,836,440 | $79,160 | $12,828,299 | $-27,765,600 |
| Net Income From Continuing And Discontinued Operation | $124,453,000 | $-4,032,000 | $52,154,000 | $-33,361,000 |
| Total Operating Income As Reported | $41,002,000 | $-22,606,000 | $11,942,000 | $3,037,000 |
| Net Income Common Stockholders | $124,453,000 | $-4,032,000 | $52,154,000 | $-33,361,000 |
| Net Income | $124,453,000 | $-4,032,000 | $52,154,000 | $-33,361,000 |
| Net Income Including Noncontrolling Interests | $124,453,000 | $-4,032,000 | $52,154,000 | $-33,361,000 |
| Net Income Discontinuous Operations | $0 | $0 | $-1,665,000 | $-28,142,000 |
| Net Income Continuous Operations | $124,453,000 | $-4,032,000 | $53,819,000 | $-5,219,000 |
| Pretax Income | $158,960,000 | $2,518,000 | $63,660,000 | $36,011,000 |
| Special Income Charges | $-6,197,000 | $-30,572,000 | $2,121,000 | $0 |
| Interest Income Non Operating | $13,659,000 | $8,055,000 | $7,711,000 | $2,046,000 |
| Operating Income | $47,199,000 | $23,021,000 | $9,821,000 | $3,037,000 |
| Depreciation Amortization Depletion Income Statement | $32,708,000 | $32,959,000 | $33,654,000 | $34,237,000 |
| Depreciation And Amortization In Income Statement | $32,708,000 | $32,959,000 | $33,654,000 | $34,237,000 |
| Amortization Of Intangibles Income Statement | $32,708,000 | $32,959,000 | $33,654,000 | $34,237,000 |
| Gross Profit | $253,538,000 | $156,059,000 | $120,802,000 | $143,418,000 |
| Per Share | ||||
| Diluted EPS | $6.13 | $-0.22 | $2.94 | $-1.98 |
| Basic EPS | $6.44 | $-0.22 | $3.02 | $-1.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $22,289,440 | $-1,092,840 | $7,495,299 | $5,993,400 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $94,544,000 | $45,998,000 | $52,351,000 | $60,804,000 |
| Total Unusual Items | $102,906,000 | $-5,204,000 | $48,486,000 | $28,540,000 |
| Total Unusual Items Excluding Goodwill | $102,906,000 | $-5,204,000 | $48,486,000 | $28,540,000 |
| Reconciled Depreciation | $33,775,000 | $35,239,000 | $36,521,000 | $51,534,000 |
| EBITDA (Bullshit earnings) | $197,450,000 | $40,794,000 | $100,837,000 | $89,344,000 |
| EBIT | $163,675,000 | $5,555,000 | $64,316,000 | $37,810,000 |
| Diluted Average Shares | $20,294,000 | $18,290,000 | $17,757,000 | $16,868,000 |
| Basic Average Shares | $19,338,000 | $18,290,000 | $17,298,000 | $16,868,000 |
| Diluted NI Availto Com Stockholders | $124,453,000 | $-4,032,000 | $52,154,000 | $-33,361,000 |
| Tax Provision | $34,507,000 | $6,550,000 | $9,841,000 | $41,230,000 |
| Gain On Sale Of Business | $0 | $0 | $2,121,000 | $0 |
| Write Off | $6,197,000 | $30,572,000 | $0 | $0 |
| Gain On Sale Of Security | $109,103,000 | $25,368,000 | $46,365,000 | $28,540,000 |
| Amortization | $32,708,000 | $32,959,000 | $33,654,000 | $34,237,000 |
| Research And Development | $81,182,000 | $21,425,000 | $24,537,000 | $36,082,000 |
| Selling General And Administration | $92,449,000 | $78,654,000 | $52,790,000 | $70,062,000 |
| Other Gand A | $92,449,000 | $78,654,000 | $52,790,000 | $70,062,000 |
| Gain On Sale Of Ppe | - | - | $2,121,000 | $0 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $690,233,000 | $458,541,000 | $297,937,000 | $139,175,000 |
| Total Assets | $1,560,637,000 | $941,774,000 | $787,216,000 | $762,668,000 |
| Total Non Current Assets | $728,366,000 | $610,215,000 | $549,787,000 | $499,067,000 |
| Other Non Current Assets | $1,788,000 | $6,924,000 | $6,392,000 | $1,736,000 |
| Non Current Deferred Assets | $8,345,000 | $72,000 | $214,000 | $8,530,000 |
| Non Current Deferred Taxes Assets | $8,345,000 | $72,000 | $214,000 | $8,530,000 |
| Financial Assets | $15,632,000 | $10,583,000 | $3,531,000 | - |
| Investmentin Financial Assets | $196,877,000 | $185,024,000 | $62,291,000 | $3,000,000 |
| Goodwill And Other Intangible Assets | $326,979,000 | $371,898,000 | $402,976,000 | $458,310,000 |
| Other Intangible Assets | $225,438,000 | $266,648,000 | $299,606,000 | $352,637,000 |
| Current Assets | $832,271,000 | $331,559,000 | $237,429,000 | $263,601,000 |
| Other Current Assets | $5,785,000 | $8,806,000 | $2,657,000 | $2,267,000 |
| Inventory | $9,126,000 | $14,114,000 | $23,969,000 | $13,294,000 |
| Receivables | $61,047,000 | $42,449,000 | $39,312,000 | $35,038,000 |
| Taxes Receivable | $1,446,000 | $4,073,000 | $6,395,000 | $4,614,000 |
| Accounts Receivable | $59,601,000 | $38,376,000 | $32,917,000 | $30,424,000 |
| Cash Cash Equivalents And Short Term Investments | $756,313,000 | $266,190,000 | $170,309,000 | $211,870,000 |
| Cash And Cash Equivalents | $174,927,000 | $72,307,000 | $22,954,000 | $45,006,000 |
| Prepaid Assets | - | $1,934,000 | $1,182,000 | $1,132,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Non Current Accounts Receivable | - | - | - | - |
| Debt | ||||
| Net Debt | $271,265,000 | - | - | $31,689,000 |
| Total Debt | $451,491,000 | $7,081,000 | $6,165,000 | $87,746,000 |
| Long Term Debt And Capital Lease Obligation | $450,396,000 | $5,815,000 | $5,755,000 | $10,336,000 |
| Long Term Debt | $446,192,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $1,095,000 | $1,266,000 | $410,000 | $77,410,000 |
| Current Debt | - | - | - | $76,695,000 |
| Other Current Borrowings | - | - | - | $76,695,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $543,425,000 | $111,335,000 | $86,303,000 | $165,183,000 |
| Total Non Current Liabilities Net Minority Interest | $505,978,000 | $74,223,000 | $69,521,000 | $66,373,000 |
| Other Non Current Liabilities | $19,563,000 | $17,700,000 | $17,000,000 | $25,378,000 |
| Non Current Deferred Liabilities | $36,019,000 | $50,708,000 | $46,766,000 | $30,659,000 |
| Non Current Deferred Taxes Liabilities | $36,019,000 | $32,524,000 | $31,622,000 | $30,615,000 |
| Current Liabilities | $37,447,000 | $37,112,000 | $16,782,000 | $98,810,000 |
| Other Current Liabilities | $422,000 | $1,508,000 | $256,000 | $57,000 |
| Current Deferred Liabilities | $621,000 | $621,000 | $1,843,000 | $976,000 |
| Payables And Accrued Expenses | $28,921,000 | $28,195,000 | $9,591,000 | $14,166,000 |
| Interest Payable | $1,307,000 | $0 | - | - |
| Payables | $6,230,000 | $11,591,000 | $2,427,000 | $5,307,000 |
| Total Tax Payable | $2,992,000 | $6,358,000 | $0 | - |
| Income Tax Payable | $1,239,000 | $1,199,000 | $0 | - |
| Accounts Payable | $3,238,000 | $5,233,000 | $2,427,000 | $5,307,000 |
| Tradeand Other Payables Non Current | - | - | $14,039,000 | $21,421,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $1,017,212,000 | $830,439,000 | $700,913,000 | $597,485,000 |
| Total Equity Gross Minority Interest | $1,017,212,000 | $830,439,000 | $700,913,000 | $597,485,000 |
| Stockholders Equity | $1,017,212,000 | $830,439,000 | $700,913,000 | $597,485,000 |
| Gains Losses Not Affecting Retained Earnings | $8,455,000 | $-5,942,000 | $-817,000 | $-984,000 |
| Other Equity Adjustments | $8,455,000 | $-5,942,000 | $-817,000 | $-984,000 |
| Retained Earnings | $608,088,000 | $498,984,000 | $503,016,000 | $450,862,000 |
| Long Term Equity Investment | $46,500,000 | $0 | $12,595,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $19,774,000 | $19,106,000 | $17,556,000 | $16,951,000 |
| Share Issued | $19,774,000 | $19,106,000 | $17,556,000 | $16,951,000 |
| Tangible Book Value | $690,233,000 | $458,541,000 | $297,937,000 | $139,175,000 |
| Invested Capital | $1,463,404,000 | $830,439,000 | $700,913,000 | $674,180,000 |
| Working Capital | $794,824,000 | $294,447,000 | $220,647,000 | $164,791,000 |
| Capital Lease Obligations | $5,299,000 | $7,081,000 | $6,165,000 | $11,051,000 |
| Total Capitalization | $1,463,404,000 | $830,439,000 | $700,913,000 | $597,485,000 |
| Additional Paid In Capital | $400,649,000 | $337,377,000 | $198,696,000 | $147,590,000 |
| Capital Stock | $20,000 | $20,000 | $18,000 | $17,000 |
| Common Stock | $20,000 | $20,000 | $18,000 | $17,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $18,184,000 | $15,144,000 | $44,000 |
| Long Term Capital Lease Obligation | $4,204,000 | $5,815,000 | $5,755,000 | $10,336,000 |
| Current Deferred Revenue | $621,000 | $621,000 | $1,843,000 | $976,000 |
| Current Capital Lease Obligation | $1,095,000 | $1,266,000 | $410,000 | $715,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,388,000 | $5,522,000 | $4,682,000 | $6,201,000 |
| Current Accrued Expenses | $22,691,000 | $16,604,000 | $7,164,000 | $8,859,000 |
| Investments And Advances | $364,828,000 | $195,932,000 | $111,612,000 | $3,000,000 |
| Other Investments | $121,451,000 | $10,908,000 | $36,726,000 | - |
| Available For Sale Securities | $196,877,000 | $185,024,000 | $62,291,000 | $3,000,000 |
| Goodwill | $101,541,000 | $105,250,000 | $103,370,000 | $105,673,000 |
| Net PPE | $10,794,000 | $24,806,000 | $25,062,000 | $27,491,000 |
| Accumulated Depreciation | $-6,578,000 | $-8,268,000 | $-6,655,000 | $-10,125,000 |
| Gross PPE | $17,372,000 | $33,074,000 | $31,717,000 | $37,616,000 |
| Leases | $2,518,000 | $10,464,000 | $10,363,000 | $7,446,000 |
| Construction In Progress | $0 | $4,219,000 | $4,115,000 | - |
| Other Properties | $9,774,000 | $9,673,000 | $9,455,000 | $15,009,000 |
| Machinery Furniture Equipment | $5,080,000 | $8,718,000 | $7,784,000 | $15,161,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $581,386,000 | $193,883,000 | $147,355,000 | $166,864,000 |
| Current Provisions | - | - | - | - |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $38,045,000 | $77,407,000 | $-4,272,000 | $119,927,000 |
| Operating Activities | ||||
| Operating Cash Flow | $49,359,000 | $97,047,000 | $49,577,000 | $137,850,000 |
| Cash Flow From Continuing Operating Activities | $49,359,000 | $97,047,000 | $49,577,000 | $137,850,000 |
| Operating Gains Losses | $-171,817,000 | $-11,749,000 | $-47,785,000 | $-32,896,000 |
| Investing Activities | ||||
| Capital Expenditure | $-11,314,000 | $-19,640,000 | $-53,849,000 | $-17,923,000 |
| Investing Cash Flow | $-377,322,000 | $-143,664,000 | $-11,682,000 | $163,624,000 |
| Cash Flow From Continuing Investing Activities | $-377,322,000 | $-143,664,000 | $-11,682,000 | $163,624,000 |
| Net Other Investing Changes | $-4,660,000 | $-2,500,000 | - | $-960,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-15,000,000 | $0 | $0 | $0 |
| Issuance Of Capital Stock | $0 | $37,140,000 | $0 | $0 |
| Financing Cash Flow | $428,223,000 | $97,141,000 | $-59,947,000 | $-275,990,000 |
| Cash Flow From Continuing Financing Activities | $428,223,000 | $97,141,000 | $-59,947,000 | $-275,990,000 |
| Net Other Financing Charges | $-25,301,000 | $-5,562,000 | $-5,496,000 | $-18,219,000 |
| Net Common Stock Issuance | $-15,000,000 | $37,140,000 | $0 | $0 |
| Common Stock Issuance | $0 | $37,140,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-113,277,000 | $-25,000 | $-76,899,000 | $-261,003,000 |
| Issuance Of Debt | $466,910,000 | $0 | $0 | - |
| Interest Paid Supplemental Data | $321,000 | $263,000 | $288,000 | $1,428,000 |
| Income Tax Paid Supplemental Data | $7,802,000 | $19,206,000 | $8,770,000 | $11,642,000 |
| End Cash Position | $174,927,000 | $72,307,000 | $22,954,000 | $45,006,000 |
| Beginning Cash Position | $72,307,000 | $22,954,000 | $45,006,000 | $19,522,000 |
| Effect Of Exchange Rate Changes | $2,360,000 | $-1,171,000 | $0 | $0 |
| Changes In Cash | $100,260,000 | $50,524,000 | $-22,052,000 | $25,484,000 |
| Proceeds From Stock Option Exercised | $114,891,000 | $65,588,000 | $22,448,000 | $3,232,000 |
| Common Stock Payments | $-15,000,000 | $0 | $0 | $0 |
| Net Issuance Payments Of Debt | $353,633,000 | $-25,000 | $-76,899,000 | $-261,003,000 |
| Net Long Term Debt Issuance | $353,633,000 | $-25,000 | $-76,899,000 | $-261,003,000 |
| Long Term Debt Payments | $-113,277,000 | $-25,000 | $-76,899,000 | $-261,003,000 |
| Long Term Debt Issuance | $466,910,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $-363,221,000 | $43,237,000 | $67,403,000 | $183,165,000 |
| Sale Of Investment | $377,284,000 | $269,621,000 | $194,167,000 | $234,391,000 |
| Purchase Of Investment | $-740,505,000 | $-226,384,000 | $-126,764,000 | $-51,226,000 |
| Net Business Purchase And Sale | $-8,388,000 | $-172,190,000 | $-25,654,000 | $-750,000 |
| Purchase Of Business | $-8,388,000 | $-172,190,000 | $-25,654,000 | $-750,000 |
| Net Intangibles Purchase And Sale | $-601,000 | $-10,390,000 | $-49,910,000 | $92,000 |
| Sale Of Intangibles | $10,261,000 | $7,429,000 | $418,000 | $92,000 |
| Purchase Of Intangibles | $-10,862,000 | $-17,819,000 | $-50,328,000 | $0 |
| Net PPE Purchase And Sale | $-452,000 | $-1,821,000 | $-3,521,000 | $-17,923,000 |
| Purchase Of PPE | $-452,000 | $-1,821,000 | $-3,521,000 | $-17,923,000 |
| Change In Working Capital | $-12,665,000 | $19,356,000 | $-34,402,000 | $65,677,000 |
| Change In Other Working Capital | $-1,798,000 | $2,293,000 | $-16,227,000 | $1,640,000 |
| Change In Payables And Accrued Expense | $5,882,000 | $13,903,000 | $-4,704,000 | $-3,340,000 |
| Change In Inventory | $4,988,000 | $9,619,000 | $-10,870,000 | $12,058,000 |
| Change In Receivables | $-21,737,000 | $-6,459,000 | $-2,601,000 | $55,319,000 |
| Changes In Account Receivables | $-21,737,000 | $-6,459,000 | $-2,601,000 | $55,319,000 |
| Other Non Cash Items | $4,841,000 | $3,703,000 | $6,044,000 | $5,872,000 |
| Stock Based Compensation | $46,849,000 | $41,089,000 | $25,743,000 | $60,285,000 |
| Asset Impairment Charge | $6,197,000 | $30,572,000 | $924,000 | $0 |
| Amortization Of Securities | $-4,958,000 | $-1,331,000 | $-1,318,000 | $16,000 |
| Deferred Tax | $22,684,000 | $-15,800,000 | $11,696,000 | $20,723,000 |
| Deferred Income Tax | $22,684,000 | $-15,800,000 | $11,696,000 | $20,723,000 |
| Depreciation Amortization Depletion | $33,775,000 | $35,239,000 | $36,521,000 | $51,534,000 |
| Depreciation And Amortization | $33,775,000 | $35,239,000 | $36,521,000 | $51,534,000 |
| Depreciation | $33,775,000 | $35,239,000 | $36,521,000 | $51,534,000 |
| Earnings Losses From Equity Investments | $-90,670,000 | $41,609,000 | $1,829,000 | $0 |
| Gain Loss On Investment Securities | $-19,455,000 | $-47,891,000 | $-46,615,000 | $-28,540,000 |
| Gain Loss On Sale Of Business | $-53,072,000 | $0 | $-2,121,000 | $0 |
| Net Income From Continuing Operations | $124,453,000 | $-4,032,000 | $52,154,000 | $-33,361,000 |
| Unrealized Gain Loss On Investment Securities | - | $25,788,000 | $0 | $0 |
| Change In Payable | - | - | $-4,704,000 | $-3,340,000 |
| Change In Account Payable | - | - | $-4,704,000 | $-3,340,000 |
| Provisionand Write Offof Assets | - | - | $3,595,000 | $0 |
| Amortization Cash Flow | - | - | $-878,000 | $-164,000 |
| Amortization Of Intangibles | - | - | $-878,000 | $-164,000 |
| Sale Of Business | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-24